Navigation Links
Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
Date:3/5/2013

DUBLIN, March 5, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the pricing of a previously announced underwritten public offering of 5,375,000 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $58.50 per share. Jazz Pharmaceuticals will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering, and its total number of ordinary shares outstanding will not change as a result of the offering. The offering is expected to close on or about March 8, 2013, subject to customary closing conditions.

Barclays Capital Inc. is acting as sole book-running manager and underwriter in this offering.

A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission ("SEC"). A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and related prospectus, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 1-888-603-5847, or by email at Barclaysprospectus@broadridge.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD, FazaClo LD, and Luvox CR® (fluvoxamine maleate). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the public offering of ordinary shares of Jazz Pharmaceuticals. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in its Annual Report on Form 10-K for the year ended December 31, 2012. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... HARRISBURG, Pa. , Jan. 17, 2017 ... Drug and Alcohol Programs Secretary Gary Tennis ... with carfentanil, following two recent overdose deaths from the ... "Carfentanil is intended to sedate large animals ... potentially kill anyone who comes into contact with it," ...
(Date:1/17/2017)... EU5 Glucose Monitoring Market Outlook to 2022 ... Monitoring Market Outlook to 2022", provides key market data ... value, in millions of US dollars, volume (in units) ... Glucose Meters, Blood Glucose Test Strips and Lancets. ... data for each of these market segements, and global ...
(Date:1/17/2017)... 2017 The interventional radiology products market is ... USD 6.35 billion in 2016, at a CAGR of ... this market are rising incidence of chronic diseases, rising ... The global interventional radiology products market is ... the basis of type, the stents segment is expected ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics ... at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, 2017. , ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the first time support an aid project with the donation of cochlear implants. ... the gift of hearing and thus a fair chance of leading an independent ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... dental problems ranging from gum disease to enamel erosion, and those dental problems ... Massachusetts Department of Public Health, many pregnant women are failing to get the ...
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), ... lurk in the corners and commit the crime of stalking, a very real danger to ... an often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. ...
(Date:1/17/2017)... ... 2017 , ... Gym Source, America’s leading retailer of premium residential and commercial ... in Miami, FL. , “We are elated to be opening this new showroom,” explains ... designed to give clients a seamless and motivating shopping experience.” , Every fitness journey ...
Breaking Medicine News(10 mins):